In continuation of my update on gemcitabine
Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint: Oncolytics Biotech Inc. announced the interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.
1 comment:
This information is really very important for me. Thank you very much for such useful information.
FOR BEST SOLUTIONS ON HEPATITIS.
Post a Comment